In the span of a year, the Supreme Court's overturning of Roe v. Wade has ushered in a new era of litigation in the anti-abortion movement that's being spearheaded by doctors challenging the Food and Drug Administration's "accelerated approval" regimen that allowed the 2000 approval of a common abortion drug known as mifepristone."There is a real irony here," Case Western Reserve University professor Jessie Hill said, noting the Dobbs v.
Notably, most of the pharmaceutical signatories on briefs against the ruling are not involved in reproductive health, revealing that their interest in protesting the decision is less to do with their stance on reproductive health and more to do with maintaining the status quo for drug approvals. "In administrative law, there's this general philosophy you defer to the federal agency that has the scientific knowledge and expertise," Corbin said, adding that even a partial upholding of Kacsmaryk's ruling could jeopardize other FDA-approved drugs. Some experts have suggested litigants could go after the pill commonly taken in tandem with mifepristone, a drug known as misoprostol.
Doctors against abortion practices that sued over the FDA's approval are represented by the Alliance Defending Freedom, a legal firm that was pivotal in overturning Roe through its defense of Mississippi's 15-week abortion law.